3. LEARNING OBJECTIVES
At the end of this class you will be able to
ï¶Define CHD
ï¶List the common cyanotic and acyanotic heart conditions
ï¶Discuss CHF
ï¶Explain infective endocarditis in children
ï¶Explain ARF in children
#222 3
5. CONGENITAL HEART DISEASE
ï¶A problem in the structure of the heart that is present at birth
ï¶Symptoms can vary from none to life-threatening
symptoms include:- Rapid breathing, bluish skin, poor
weight gain, and feeling tired.
- It does not cause chest pain
#222 5
7. CONTâŠ
ï¶Syndrome complexes
- VACTREL syndrome - Vertebral, Anorectal,
Cardiac(VSD,TOF and others),Tracheal, Renal, Oesophageal
and Limb abnormalities
ï¶But the majority of cases of the congenital heart diseases are
unknown cause
#222 7
9. CONTâŠ
2. Cyanotic congenital heart disease (4TâS)
ï¶Tetralogy of fallot
ï¶Truncus arteriosus
ï¶Transposition of great arteries
ï¶Tricuspid atresia
#222 9
10. ACYANOTIC CONGENITAL HEART
DISEASE
ï¶Blood is shunted (flows) from the left side of the heart to the
right side of the heart due to a structural defect (hole) in the
inter-ventricular septum.
ï¶Communication between the systemic and pulmonary sides
of the circulation, which results in shunting of fully
oxygenated blood back into the lungs.
#222 10
11. VENTRICULAR SEPTAL
DEFECT (VSD)
ï¶Is a defect in the ventricular septum, the wall dividing the
left and right ventricles of the heart.
Cause
ï¶Other congenital conditions, such as Down syndrome
ï¶Incomplete looping of the heart during days 24-28 of
development
#222 11
12. CONTâŠ
Clinical Manifestation
ï¶Symptomless at birth - usually manifests a few weeks after
birth.
ï¶Infant with a large VSD will fail to thrive and become
sweaty and tachypnoeic (breathe faster) with feeds.
ï¶Pulmonary hypertension due to the increased blood flow
#222 12
13. CONTâŠ
Diagnosis
ï¶Can be detected by cardiac auscultation - pansystolic murmur
Treatment
ï¶Most cases do not need treatment and heal at the first years of
life.
ï¶Smaller congenital VSDs often close on their own
#222 13
16. CONTâŠ
Surgical Intervention:- Indications
1. Failure of congestive cardiac failure to respond to medications
2. VSD with pulmonic stenosis
3. Large VSD with pulmonary hypertension
4. VSD with aortic regurgitation
#222 16
17. ATRIAL SEPTAL DEFECT
ï¶Blood flows between the atria (upper chambers) of the heart
Causes
ï¶Down syndrome
ï¶Ebstein's anomaly
ï¶Fetal alcohol syndrome
ï¶HoltâOram syndrome
ï¶Lutembacher's syndrome
#222 17
20. CONTâŠ
Diagnosis
ï¶Individuals with a significant ASD are diagnosed in utero or
in early childhood with the use
of ultrasonography or auscultation of the heart
sounds during physical examination
ï¶Chest X-ray, ECG or EKG, Cardiac catheterization
#222 20
22. PATENT DUCTUS ARTERIOSUS (PDA)
ï¶Is a condition where the ductus arteriosus fails to close
after birth.
ï¶Resulting in irregular transmission of blood between
the aorta and the pulmonary artery
#222 22
23. CONTâŠ
Cause
ï¶PDA is sometimes idiopathic. Known risk factors include:
ï¶Preterm birth
ï¶Congenital rubella syndrome
ï¶Chromosomal abnormalities (e.g., Down syndrome)
ï¶Genetic conditions such as Loeys-Dietz syndrome (would also
present with other heart defects)
#222 23
24. CONTâŠ
Sign and symptom
ï¶Tachycardia
ï¶Respiratory problems - Dyspnea (shortness of breath)
ï¶Continuous "machine-like" (also described as "rolling-thunder"
and "to-and-fro") heart murmur
ï¶Cardiomegaly (enlarged heart, reflecting ventricular
dilation and volume overload)
#222 24
25. CONTâŠ
ï¶Left subclavicular thrill
ï¶Bounding pulse
ï¶Widened pulse pressure
ï¶Poor growth
ï¶Differential cyanosis, i.e. cyanosis of the lower extremities
but not of the upper body.
#222 25
27. CONTâŠ
Treatment
ï¶PDA can be treated with both surgical and non-surgical
methods
ï¶ Non surgical treatment
- Indomethacin or a special form of ibuprofen have
been used to initiate PDA closure
#222 27
28. CONTâŠ
Prevention
ï¶Some evidence suggests that indomethacin administration on the
first day of life to all preterm infants reduces the risk of developing a
PDA and the complications associated with PDA. Indomethacin
treatment in premature infants also may reduce the need for surgical
intervention
#222 28
29. CYANOTIC HEART DEFECT
ï¶ Is a group-type of congenital heart defect (CHD) that occurs
due to deoxygenated blood bypassing the lungs and entering
the systemic circulation or a mixture of oxygenated and
unoxygenated blood entering the systemic circulation.
#222 29
32. TETRALOGY OF FALLOT (TOF)
ï¶The primary defect is an anterior deviation of the
infundibular septum (the muscular septum that separates the
aortic and pulmonary outflows).
#222 32
33. TOF CONTâŠ
The consequences of this deviation are the 4 components:
1. Obstruction to right ventricular outflow (pulmonary
stenosis),
2. Ventricular septal defect (VSD),
3. Dextroposition of the aorta so that it overrides the
ventricular septum (overriding aorta), and
4. Right ventricular hypertrophy
#222 33
34. CONTâŠ
Clinical manifestation
ï¶Episodes of bluish color to the skin.
ï¶When affected babies cry or have a bowel movement they may
develop a "tet spell" where they turn very blue,
ï¶Have a hard time breathing, become limp, and
#222 34
36. CONTâŠ
ï¶Risk factors include
- A mother who uses alcohol,
- Has diabetes,
- Is over the age of 40,
- Rubella during pregnancy
- Down syndrome
#222 36
38. TRANSPOSITION OF THE GREAT VESSELS
ï¶Is a group of congenital heart defects involving an abnormal
spatial arrangement of any of the great vessels.
Risk factors
ï¶Preexisting diabetes mellitus of a pregnant mother
Diagnosis
ï¶Chest X-ray
#222 38
39. CONTâŠ
Treatment
ï¶ Prostaglandins can be given to keep the ductus arteriosus open
ï¶Arterial switch operation is the definitive treatment for dextro-
transposition
#222 39
40. TRUNCUS ARTERIOSUS
ï¶Also called Common arterial trunk
ï¶Is a rare form of congenital heart disease that presents at
birth.
ï¶In this condition, the embryological structure known as
the truncus arteriosus fails to properly divide into
the pulmonary trunk and aorta
#222 40
41. CONTâŠ
Clinical Manifestations
ï¶Cyanosis presents at birth
ï¶Heart failure may occur within weeks
ï¶Systolic ejection murmur is heard at the left sternal border
ï¶Widened pulse pressure
ï¶Bounding arterial pulses
#222 41
44. TRICUSPID ATRESIA
ï¶There is a complete absence of the tricuspid valve
ï¶Therefore, there is an absence of right atrioventricular
connection. This leads to a hypoplastic (undersized) or
absent right ventricle.
Causes
Causes of Tricupsid atresia are unknown.
#222 44
46. CONTâŠ
ï¶Holosystolic murmur due to the VSD
ï¶left axis deviation on electrocardiography and left ventricular
hypertrophy (since it must pump blood to both the pulmonary
and systemic systems)
ï¶normal heart size
#222 46
47. CONTâŠ
Treatment
ï¶PGE1 to maintain patent ductus arteriosus
ï¶Modified Blalock-Taussig shunt to maintain pulmonary blood
flow.
ï¶Cavopulmonary anastomosis to provide stable pulmonary flow
ï¶Fontan procedure to redirect inferior vena cava and hepatic
vein flow into the pulmonary circulation
#222 47
48. CONGESTIVE HEART FAILURE
ï¶Cardiac output--- Stroke volume X Heart rate
ï¶Heart rate varies with age
ï¶Stroke volume is the amount of blood ejected per beat
ï¶Preloadâ the amount of blood returning to the heart during
diastole
ï¶After loadâthe amount of pressure exerted against ventricular
ejection during systole
#222 48
49. CHF
Definition: It is a state of decreased cardiac output with failure to
met metabolic needs
Decreased cardiac output could be due to
ï¶1. Poor contractility
ï¶2. Decreased preload
ï¶3. Increased after load
ï¶4. Decreased in heart rate #222 49
53. CONTâŠ
Precordial examination may show
ï¶Bulged chest, hyperdynamic precordium
ï¶Diastolic and or Systolic murmur
ï¶Hepatomegaly, ascites
ï¶Crepitations and wheezing due to pulmonary edema
#222 53
55. CONTâŠ
2. Congenital heart diseases (CHD)
A. Acyanotic CHD (Left to right shunt)
ïPDA, VSD, ASD etc
B. Cyanotic CHD (right to left shunt)
ïTetralogy of fallot, Truncus arteriosus
ïTricuspid atresia, Transposition of great arteries
#222 55
56. DIAGNOSIS OF CHF
Clinical examination
ï¶CXR: to show cardiomegaly, pulmonary edema etc
ï¶Echocardiography: differentiate acquired from congenital heart
diseases, severity, presence of infective endocarditis
ï¶ECG: Detection of rhythm disturbances, cavity dilatation, axis
deviation and hypertrophy
#222 56
58. TREATMENT OF CHF
A. Medical therapy
1. Reduction of volume overload
ï¶Furosemide, chlorthiazide, reduce salt intake
2. Increase heart contractility
ï¶Digoxin, Dopamine
#222 58
59. CONTâŠ
3. Inhibit salt and water reabsorption
ï¶Captopril, enalapril, Spironolactone
4. Decrease afterload (resistance)
ï¶Captopril, enalapril
#222 59
60. TREATMENT OF CHF
Surgical therapy
ï¶Correction of structural defect in congenital heart disease
(PDA, VSD, ASD, TOF, TGA, TA)
ï¶Closed surgery to correct septal defects
ï¶Open surgery to correct complicated heart defects
ï¶Valve repair or replacement for rheumatic heart disease
#222 60
61. INFECTIVE ENDOCARDITIS
Infectious Endocarditis (IE): an infection of the heartâs
endocardial surface
ï¶Classified into four groups:
âą Native Valve IE
âą Prosthetic Valve IE
âą Intravenous drug abuse (IVDA) IE
âą Nosocomial IE
#222 61
62. ï¶Acute
âą Affects normal heart valves
âą Rapidly destructive
âą Metastatic foci
âą Commonly Staph.
âą If not treated, usually fatal
within 6 weeks
FURTHER CLASSIFICATION
ï¶Sub-acute
âą Often affects damaged heart
valves
âą Indolent nature
âą If not treated, usually fatal by
one year
#222 62
63. ETIOLOGIC AGENTS IN PEDIATRIC
INFECTIVE ENDOCARDITIS
COMMON: NATIVE VALVE OR OTHER CARDIAC
LESIONS
âą Viridans group streptococci (S. mutans, S. sanguis, S.
mitis)
âą Staphylococcus aureus
âą Group D streptococcus (enterococcus) (S. bovis, S.
faecalis)
#222 63
64. EPIDEMIOLOGY
ï¶Often a complication of congenital or rheumatic heart disease
ï¶Can also occur in children without any abnormal valves or
cardiac malformations.
ï¶Rare in infancy; in this age group, it usually follows open heart
surgery or is associated with a central venous line
#222 64
65. EPIDEMIOLOGY
ï¶Patients with congenital heart lesions in which blood is
ejected at high velocity through a hole or stenotic orifice are
most susceptible to endocarditis.
ï¶Vegetations usually form at the site of the endocardial or
intimal erosion that results from the turbulent flow
#222 65
66. PATHOPHYSIOLOGY
1. Turbulent blood flow disrupts the endocardium making it
âstickyâ
2. Bacteremia delivers the organisms to the endocardial
surface
3. Adherence of the organisms to the endocardial surface
4. Eventual invasion of the valvular leaflets
#222 66
67. CLINICAL MANIFESTATIONS
HISTORY
âą Prior congenital or rheumatic heart disease
âą Preceding dental, urinary tract, or intestinal
procedure
âą Intravenous drug use
âą Central venous catheter
âą Prosthetic heart valve
#222 67
68. CLINICAL MANIFESTATIONS
ï¶SYMPTOMS
âą Fever, Chills
âą Chest and abdominal pain
âą Arthralgia
âą Dyspnea
âą Night sweats, Weight loss
âą CNS manifestations (stroke, seizures, headache
#222 68
69. CLINICAL MANIFESTATIONS
SIGNS
âą Elevated temperature
âą Tachycardia
âą Vascular- Embolic phenomena (Roth spots, petechiae,
splinter nail bed hemorrhages, CNS or ocular lesions)
#222 69
72. PETECHIAE
Photo credit, Josh Fierer, M.D.
medicine.ucsd.edu/clinicalimg/ Eye-Petechiae.html
Harden Library for the Health Sciences
www.lib.uiowa.edu/ hardin/
md/cdc/3184.html
1.Nonspecific
2.Often located on extremities
or mucous membranes
dermatology.about.com/.../
blpetechiaephoto.htm
#222 72
74. OSLERâS NODES
1.More specific
2.Painful and erythematous nodules
3.Located on pulp of fingers and toes
4.More common in sub-acute IE
American College of Rheumatology
webrheum.bham.ac.uk/.../ default/pages/3b5.htm www.meddean.luc.edu/.../
Hand10/Hand10dx.html
#222 74
78. DIAGNOSTIC (DUKE) CRITERIA
ï¶Definitive infective endocarditis
âą Pathologic criteria
âą microorganisms or pathologic lesions: demonstrated by
culture or histology in a vegetation, or in a vegetation that
has embolized, or in an intracardiac abscess
âą Clinical criteria
âą two major criteria, or one major and three minor criteria, or
five minor criteria
#222 78
79. DIAGNOSTIC (DUKE) CRITERIA
ï¶Possible infective endocarditis
âą findings consistent of IE that fall short of âdefiniteâ, but not ârejectedâ
ï¶Rejected
âą firm alternate Dx for manifestation of IE
âą resolution of manifestations of IE, with antibiotic therapy for ïŁ 4 days
âą no pathologic evidence of IE at surgery or autopsy, after antibiotic therapy
for ïŁ 4 days
#222 79
81. CONTâŠ
Minor criteria
âą Predisposing conditions (heart condition or IV drug use)
âą Fever of 100.40F or higher
âą Embolic â vascular phenomena
âą Immunologic phenomena
âą Microbiologic evidence not meeting major criteria
âą Echocardiographic evidence not meeting major criteria
#222 81
82. THE ESSENTIAL BLOOD TEST
ï¶Blood Cultures
âą Minimum of three blood samples
âą Three separate venipuncture sites
âą Obtain 10-20mL in adults and 0.5-5mL in children
#222 82
83. CONTâŠ
ï¶Positive Result
âą Typical organisms present in at least 2 separate samples
âą Persistently positive blood culture (atypical organisms)
âą Two positive blood cultures obtained at least 12 hours apart
âą Three or a more positive blood cultures in which the first
and last samples were collected at least one hour apart
#222 83
84. DUKEâS MAJOR CRITERIA
ï¶Evidence of endocardial involvement (Echocardiography)
âą Intracardiac mass on a valve or other site
âą Regurgitant flow near a prosthesis
âą Abscess
âą Partial dehiscence of prosthetic valves
âą New valve regurgitant flow
#222 84
86. EMBOLIC COMPLICATIONS
ï¶Occur in up to 40% of patients with IE
ï¶Predictors of embolization
âą Size of vegetation
âą Left-sided vegetation
âą Fungal pathogens, S. aurous, and Strep. Bovis
ï¶Incidence decreases significantly after initiation of effective
antibiotics
#222 86
88. LOCAL SPREAD OF INFECTION
ï¶Heart failure
âą Extensive valvular damage
âą Myocardial abscesses
âą Toxic myocarditis
ï¶Paravalvular abscess (30-40%)
âą Most common in aortic valve, IVDA, and S. aureus
âą Higher rates of embolization and mortality
#222 88
89. LOCAL SPREAD OF INFECTIONâŠ
ï¶Arrythmias
ï¶Heart block
ï¶Valve obstruction
ï¶Pericarditis
ï¶Fistulous intracardiac connections
E.g. , acquired VSD
#222 89
92. MEDICAL TREATMENT
ï¶Pre-antibiotic era - a death sentence
ï¶Antibiotic era
âą microbiologic cure in majority of patients
ï¶Parenteral antibiotics
âą High serum concentrations to penetrate vegetations
âą Prolonged treatment to kill dormant bacteria clustered in
vegetations
#222 92
93. MEDICAL TREATMENT
ï¶A total of 4â6 wk of treatment is recommended, with
serumcidal levels by tube dilution of at least 1:8 after a dose of
antibiotic.
ï¶Depending on the clinical and laboratory responses, antibiotic
therapy may require modification and, in some instances, more
prolonged treatment is required.
#222 93
94. MEDICAL TREATMENT
ï¶In nonstaphylococcal disease, bacteremia usually resolves in
24â48 hr, whereas fever resolves in 5â6 days with appropriate
antibiotic therapy.
ï¶Resolution with staphylococcal disease takes longer
#222 94
95. MEDICAL TREATMENT
ï¶Determinants of choice of antibiotics
âą Type of endocarditis
âą Native valve
âą Prosthetic valve
âą Etiologic agent
âą Sensitivity of the etiologic agent to drugs
#222 95
96. MEDICAL TREATMENT:
BACTERIAL
Commonly used antibiotic combination:
Aqueous crystalline penicillin G sodium
or
Ceftriaxone sodium
plus
Gentamicin sulfate
Plus
Vancomycin hydrochloride
#222 96
100. SURGICAL TREATMENT :
INDICATIONS
âą Severe aortic or mitral valve involvement with intractable
heart failure
âą Rupture of an aortic sinus
âą Dehiscence of an intracardiac patch
âą Failure to sterilize the blood despite adequate antibiotic
level
#222 100
102. PROGNOSIS
ï¶In the pre-antibiotic era, infective endocarditis was a fatal
disease.
ï¶Despite the use of antibiotic agents, mortality remains at 20â
25%.
ï¶Serious morbidity occurs in 50â60% of children with
documented infective endocarditis
#222 102
104. PREVENTION.
ï¶In patients with high or moderate risk heart conditions,
antimicrobial prophylaxis before various procedures:
âą dental and oral procedures
âą surgery of the upper respiratory tract
âą Surgery of the GI tract
âą Urinary tract procedures
ï¶Continuing education regarding the important of prophylaxis
ï¶Proper general dental care and oral hygiene
#222 104
106. ACUTE RHEUMATIC FEVER
âAcute rheumatic fever: inflammatory disease with
devastating sequelae
âLink to pharyngeal infection with group A beta hemolytic
streptocci
âContinues to be a problem worldwide:
âsporadic outbreaks in developed countries
âfrequent occurrences in developing countries
#222 106
107. CONTâŠ
âStill gaining understanding of etiology
âlink between genetic predisposition and clinical
manifestations
âBest prevention still correct use of antibiotics
#222 107
108. ï¶Etiology
âą Rheumatogenic strains of GAS serotypes (M 1, 3, 5, 6, 18,
24)
âą â of the patients with an acute episode of rheumatic fever
have a history of an upper respiratory tract infection several
weeks before
#222 108
109. Epidemiology
âą Most common form of acquired heart disease in all age
groups world wide
âą Important cause of chronic heart disease and death in
developing world
âą Estimated 30 million people suffer from ongoing heart
disease from ARF, 70% dying at average age 35 years old
#222 109
110. CONTâŠ
âą Accounts for
âą 50% of all cardiovascular disease
âą 50% of all cardiac admissions in many developing countries
ï¶In some developing areas of the world, the annual incidence is
282/100,000 population
ï¶Males and females equally affected
#222 110
111. ï¶Factors associated with acute rheumatic fever
âą Socioeconomic status
âą Overcrowding,
âą poverty,
âą lack of access to medical care
âą Virulence of strain of GAS
âą serotypes of GAS (M types 1, 3, 5, 6, 18, 24) are
associated with ARF
#222 111
112. Host factors
âą Age : peak incidence in children 5 - 15 years old
âą Previous history of acute rheumatic fever
#222 112
113. Pathogenesis
ï¶Still not clearly defined
ï¶Group A strep pharyngeal infection precedes clinical
manifestations of ARF by 2 - 6 weeks
Two seriously considered theories:
ï¶The cytotoxicity theory
âą suggests that cytotoxic effect of GAS streptolysin O toxin
may be responsible for the pathogenesis.
#222 113
114. CONTâŠ
ï¶The immunologic theory (theory of molecular mimicry)
âą Antibodies made against group A strep cross-react with
human tissue (e.g., heart, brain, joint).
#222 114
115. Clinical Features
Following upper airway infection with GAS
- Silent period of 2 - 6 weeks
- Sudden onset of fever, pallor, malaise, fatigue
#222 115
116. Clinical Features (continued)
Characterized by:
âą Arthritis
âą Carditis
âą Sydenhamâs chorea
âą Erythema marginatum
âą Subcutaneous nodules
ïŒCalled âmajor manifestationsâ of Jones criteria either because
of frequency or specificity
#222 116
117. ï¶Minor manifestations
Clinical features
âą Fever
âą Arthralgia
Laboratory features
âą Elevated c-reactive protein or
âą Erythrocyte sedimentation rate
âą Prolonged PR interval on EKG
#222 117
118. Diagnosis
ï¶ Jones criteria
âą Criteria developed to prevent overdiagnosis
âą Some criticism regarding validity but still important as guidelines
ï¶Probability of ARF high with
âą Evidence of previous infection with streptococcal upper
respiratory infection & 2 major criteria or 1 major criteria and 2
minor criteria #222 118
120. Diagnosis: Jones Criteria (continued)
âą Minor manifestations
âą Fever
âą Arthralgia
âą Elevated c-reactive protein or
erythrocyte sedimentation rate
âą Prolonged PR interval on EKG
#222 120
121. ï¶There are 3 circumstances in which the diagnosis of acute
rheumatic fever can be made without strict adherence to the
Jones criteria.
âą Chorea .
âą Indolent carditis.
âą Recurrences of acute rheumatic fever .
#222 121
122. Treatment
Supportive
âą bed rest .
âą For carditis with heart failure
âą digoxin,
âą fluid and salt restriction,
âą diuretics,
âą Oxygen
#222 122
123. CONTâŠ
Antibiotic therapy
âą 10 days of orally administered penicillin or erythromycin,
or
âą single intramuscular injection of benzathine penicillin
#222 123
124. Anti-Inflammatory Therapy
âą Agents such as acetaminophen can be used to control pain
and fever while the patient is being observed for more
definite signs of acute rheumatic fever or for evidence of
another disease.
#222 124
125. âą ASA in patients with typical migratory polyarthritis and
those with carditis
âą The usual dose of aspirin is 100 mg/kg/day in 4 divided
doses PO for 3â5 days, followed by 75mg/kg/day in 4
divided doses PO for 4 wk.
#222 125
126. âą In patients with carditis and cardiomegaly or congestive heart
failure , corticosteroids.
âą The usual dose of prednisone is 2 mg/kg/day in 4 divided
doses for 2â3 wk followed by a tapering of the dose that
reduces the dose by 5 mg/24 hr every 2â3 days.
âą At the beginning of the tapering of the prednisone dose,
aspirin should be started at 75 mg/kg/day in 4 divided
doses for 6 wk.
#222 126
128. Secondary Prevention
ï Penicillin g benzathine , every 4 wk intramuscular
ï < 27 kg: 600,000 units
ï >27 kg: 1,200,000 units
or
ï Penicillin v 250 mg, twice a day oral
or
ï Sulfadiazine or sulfisoxazole
#222 128
131. ANEMIA
Definition:-
- Physiological (functional) definition:-
- is a decrease in red cell mass and corresponding
decrement in oxygen carrying capacity.
- Laboratory definition:- when Hgb level in the blood is below
the reference level for age and sex.
#222 131
132. INTRODUCTION AND
GENERAL ASPECTS
ï¶Blood consists of: Red cells, white cells and platelets
ï¶Plasma:- the liquid component of blood, which contains
soluble fibrinogen is the place where the above elements are
suspended.
ï¶Serum is what remains after the formation of the fibrin clot.
132
#222
133. THE RED CELLS:
Red Blood Cells (Erythrocytes):
ï¶The major function of red blood cells is to transport
hemoglobin, which in turn carries oxygen from the lungs
to the tissues.
133
#222
135. CAUSES OF ANEMIAâŠ
1. Deceased red cell production :- generally develops gradually
and cause chronic anemia. This can be due to:-
a) Marrow failure ;- 2ndry to
-Marrow aplasia/hypoplasia.
- marrow infiltration.
- Transient erytroblastopenia.
#222 135
136. CAUSES OF ANEMIA
b) Impaired erythropoietin production.
- anemia of chronic disease.
-Chronic inflammatory disease.
-HIV infection
c) Defect in RBC production
- Nutritional anemia , deficiency of
Iron , folic acid, Vitamin B-12âŠ..
#222 136
137. CAUSES OF ANEMIAâŠ
2. Hemolysis (Increased red cell destruction)
a) extrinsic:- enlarged spleen, hepatitis, leukemia, lymphoma,
tumors
b) drug-induced:- antibiotics, such as penicillin, ampicillin, or
methicillin, ibuprofen
c) Intrinsic:- inherited, red blood cells produced by the body are
defective.
#222 137
138. CAUSES OF ANEMIAâŠ
3. Blood loss
- GI loss
- Pulmonary loss
- Bleeding disorder.
#222 138
139. TYPES OF ANEMIA
The most common types of anaemia are:-
- Iron deficiency anaemia
- Sickle cell anaemia
- Thalassaemia - Pernicious anaemia
- Aplastic anaemia - Fanconi anaemia
- Haemolytic anaemia
#222 139
140. ANAEMIA
ïMost common form of anaemia, is caused by:-
ï¶Chronic blood loss: Most commonly due to excessive
menstruation or bleeding into or from the gut as a result of a peptic
ulcer, gastritis, haemorrhoids or in children, worm infestation.
#222 140
141. TYPES, IRONâŠ
ï¶Increased use of iron: In pregnancy, due to the growth of the
foetus or children undergoing rapid growth spurts in infancy and
adolescence.
ï¶Decreased absorption of iron: lack of stomach acid; chronic
diarrhoea; or malabsorption.
#222 141
142. TYPES, IRONâŠ
ï¶Treated with iron supplementation(dietary changes and
supplements, medicines) as well as the treatment of the
underlying cause of the iron deficiency.
#222 142
143. APLASTIC ANAEMIA
ï¶Blood disorder in which the body's bone marrow doesn't make
enough new blood cells
ï¶Causes:- damage to the bone marrow's stem cells
ï¶Treatment:- blood transfusions, blood and marrow stem cell
transplants, and medication
#222 143
144. HAEMOLYTIC ANAEMIA
ï¶A condition in which red blood cells are destroyed and removed
from the bloodstream before their normal lifespan is up.
ï¶Cause: disease conditions
ï¶Treatment: blood transfusions, medicines, blood and marrow
stem cell transplants and lifestyle changes.
#222 144
145. THALASSAEMIA
ï¶Inherited blood disorders which cause the body to make fewer
healthy red blood cells and less haemoglobin.
ï¶Treatment: blood transfusions, iron chelation therapy, and folic
acid supplements
#222 145
146. SICKLE CELL ANAEMIA
ï¶A serious disease in which the body makes sickle-shaped
("C"-shaped) red blood cells.
ï¶Normal red blood cells are disk-shaped and move easily
through your blood vessels.
ï¶An inherited, lifelong disease
#222 146
147. SICKLEâŠ
ï¶Treatment: The goals of treating sickle cell anaemia are to
relieve pain, prevent infections, eye damage and strokes, and
control complications.
ï¶Bone marrow transplants may offer a cure in a small number of
sickle cell anaemia cases
#222 147
148. PERNICIOUS ANAEMIA
ï¶A condition in which the body can't make enough healthy red
blood cells because it doesn't have enough vitamin B12.
ï¶Cause: certain diseases that interfere with vitamin B12
absorption; certain medicines; surgical removal of part of the small
intestine; and tapeworm infection.
ï¶Treatment: treated by replacing the missing vitamin B12 in the
body.
#222 148
149. CLINICAL FEATURES
ï¶ Pallor,Weakness, malaise, and easy fatigability are common
complaints.
ï¶ Dyspnea on mild exertion.
ï¶The nails can become brittle, lose their usual convexity, and
assume a concave spoon shape (koilonychia).
149
#222
150. CLINICAL CONTâŠ
ï¶Anoxia can cause fatty change in the liver, myocardium, and
kidney.
ï¶With acute blood loss and shock, oliguria and anuria can
develop due to renal hypoperfusion.
ï¶Central nervous system hypoxia can cause headache, dimness
of vision, and faintness.
#222 150
152. TREATMENT PRINCIPLES
A. Treatment of underlying cause
B. Dietary conselling
C. Iron theraphy
D. Blood transfusion
- Sever anemia
- anemia leading to CHF
#222 152
153. LEUKAEMIAS
ï¶Leukaemias are malignant disorders of the haematopoietic
stem cell compartment, characteristically associated with
increased numbers of white cells in the bone marrow and/or
peripheral blood.
153
#222
154. CONTâŠ
ï¶The course of leukaemia may vary from a few days or weeks
to many years, depending on the type.
ï¶The most common malignant neoplasms in childhood
#222 154
155. FACTORS ASSOCIATED WITH THE
DEVELOPMENT OF LEUKAEMIA
ï¶Ionising radiation- An increase in leukaemia was observed
after the use of radiotherapy: eg-diagnostic X-rays of the fetus
in pregnancy
ï¶Cytotoxic drugs, Retroviruses
ï¶Genetic -There is a greatly increased incidence of leukaemia
in the identical twin
ï¶Immunological -Immune deficiency states. 155
#222
156. CLASSIFICATION
ï¶Leukaemias are traditionally classified into four main
groups:
âą Acute lymphoblastic leukaemia (ALL)
âą Acute myeloid leukaemia (AML)
âą Chronic lymphocytic leukaemia (CLL)
âą Chronic myeloid leukaemia (CML).
156
#222
157. CLINICAL FEATURES
ï¶The majority of patients with acute leukaemia, regardless of
subtype present with symptoms arising from:
ï¶ Anaemia - shortness of breath on effort; excessive tiredness,
weakness
ï¶Leucopoenia - recurrent infections
157
#222
161. PRINCIPLES OF
MANAGEMENT
ï¶Untreated acute leukaemia is invariably fatal, most often
within months, though with judicious palliative care it may be
extended to perhaps a year.
161
#222
162. CONTâŠ
ï¶Treatment with curative intent may be successful, or may fail,
either because the leukaemia cannot be eradicated or because the
patient cannot sustain the therapy, death occurring as early as if
treatment had not been initiated.
#222 162
163. TREATMENT OUT LINE
ï¶Treatment of complications
- Anemia â transfusion
- Infection-antibiotics
- Thrombocytopenia- platelate transfusion
ï¶Anti- neoplastic medication
ï¶BM - transplantation
#222 163
164. HAEMOPHILIA
ï¶Inherited genetic disorder that impairs the body's ability
to make blood clots, a process needed to stop bleeding.
ï¶X-linked recessive disorders females are very rarely severely
affected
#222 164
165. CONTâŠ
Types:- two main types of haemophilia:-
ï¶Haemophilia A, which occurs due to not enough
clotting factor VIII,
ï¶Haemophilia B, which occurs due to not enough
clotting factor IX
#222 165
166. CLINICAL FEATURE
ï¶Spontaneous bleeding, most characteristic type of internal
bleed is a joint bleed where blood enters into the joint spaces.
ï¶Children with mild to moderate haemophilia may not have
any signs or symptoms at birth especially if they do not
undergo circumcision.
#222 166
167. CONTâŠ
ï¶Their first symptoms are often frequent and large bruises
and haematomas from frequent bumps and falls as they learn to
walk
ï¶Diagnosis:- is by testing the blood for its ability to clot and its
levels of clotting factors
#222 167
168. COMPLICATIONS
ï¶Deep internal bleeding, e.g. deep-muscle bleeding, leading to
swelling, numbness or pain of a limb.
ï¶Joint damage from haemarthrosis potentially with severe
pain, disfigurement, and even destruction of the joint and
development of debilitating arthritis.
#222 168
169. CONTâŠ
ï¶Transfusion transmitted infection from blood transfusions
that are given as treatment
ï¶Adverse reactions to clotting factor treatment, including the
development of an immune inhibitor which renders factor
replacement less effective.
#222 169
170. CONTâŠ
ï¶Intracranial haemorrhage is a serious medical emergency
caused by the buildup of pressure inside the skull. It can cause
disorientation, nausea, loss of consciousness, brain damage,
and death.
#222 170
171. TREATMENT
ï¶Factor replacement can be either isolated from human blood
serum, recombinant, or a combination of the two.
ï¶Anticoagulants such as heparin and
warfarin are contraindicated for people with haemophilia as
these can aggravate clotting difficulties
#222 171
172. CNOTâŠ
ï¶Medicines which contain aspirin, ibuprofen, or naproxen
sodium should not be taken because they are well known to
have the side effect of prolonged bleeding
#222 172
174. âą Fracture is break in the continuity of the cortex of a bone
âą Causes:- Traumatic (High Vs Low energy Injury), Atraumatic
or Pathological
âą Mechanism of injury
âą Direct trauma
âą Indirect trauma or Combined
Fracture
#222 174
175. CLASSIFICATION
ïBased on :-
A) Site of involvement
metaphysis, diaphysis ,articular
B)Soft tissue involvement
- Closed(simple):- Fracture is not exposed to the
environment
- Open (compound) #222 175
176. CONTâŠ
B) Compound (Open) fracture
A break in the skin and underlying soft tissue leading
(directing) into or communicating with the fracture and its
hematoma
#222 176
178. INVESTIGATION
ï¶X-ray should be taken in at least two planes (AP and lateral)
ï¶Should always include the joints proximal and distal to the
fracture
ï¶Look in the X-ray for: Presence of fracture, The part of bone
fractured
#222 178
181. MANAGEMENT OF
FRACTUREâŠ
â Including vascular and neurological status
â Record all your finding
âą Emergency treatment of fractures and dislocation
â Align the fracture
â Splint
â Analgesics
#222 181
182. MANAGEMENT OF
FRACTUREâŠ
ï¶Investigation
â X- ray
âą PA and lateral X- ray (Include one joint above & one
below)
âą Special view if necessary
âą If difficulty of interpretation take X-ray of opposite side
#222 182
184. METHODS OF
IMMOBILIZATION
1- Plaster of Paris (POP) cast
- Is the safest and cheapest method of immobilization
- Immobilization should always include the two adjacent
joints
- Joints should be immobilized in a functional position
#222 184
186. IMMBILIZATION
TECHNIQUESâŠ
2. Immobilization by traction method
1. Skin traction
â Used
âą for children
âą for adults temporarily
â Weight more than 3 Kg result in skin slough
#222 186
187. REHABILITATION
ï¶ Start immediately
ï¶ Phase of rehabilitation
âą Resting
âą Properioceptive training
âą Strengthening exercise
âą Work related training
#222 187
188. PRINCIPLES OF COMPOUND
FRACTURE MANAGEMENT:
ï¶Early wound debridement and thorough irrigation with saline
ï¶Antibiotics: Broad spectrum e.g. Penicillin +
Aminoglycoside should be given IV at least for 48 hrs.
ï¶Tetanus prophylaxis
#222 188
189. CONTâŠ
ï¶Rigid immobilization with access to the wound e.g. external
fixation
ï¶Delayed wound closure!
ï¶Never close a compound fracture immediately in an attempt
to convert it to a closed one. Youâll cause a severe anaerobic
infection
#222 189
191. CONGENITAL TALIPUS EQUINO
VARUS ( CTEV)
âą The hill is inverted
âą Fore foot & mid foot âinverted & adducted (Varus)
âą Ankle is equines
191
âą Twist of calcaneum and navicular around the
talus
#222
197. DIAGNOSIS
ï¶ C/F
âą Club like appearance
âą Foot point plantar
âą Small heal, drown up &
inverted
âą Deep creases at posterior
ankle
197
#222
199. TREATMENT
ï¶ Start as soon as possible
ï¶ Extend until skeletal maturity
ï¶ Never be completely normal
1. Conservative
âą Streaching â count 10/20-30 times/
several times per day
199
#222
201. FOLLOW UP
After operation
âą 3 serial cast
âą Club foot shoe
201
Neglected CTEV â Triple fusion (after the age of 10-
12yrs)
âą Talo-Calcanial
âą Talo-Navicular
âą Calcaneo-cuboid
#222
203. OSTEOMYELITIS
ï¶Inflammation of the bone due to pathogenic infection
Epidemiology
ï¶Common in children
ï¶Males are affected twice more than girls
ï¶Direct inoculation in older children
ï¶Bactremia in neonates and infants
#222 203
205. CONTâŠ
ï¶Long bones of the extremities are affected most
Etiology
ï¶S. aureus, S. pneumoniae, H. influenzae
ï¶Pseudomonas, M. tuberculosis, salmonella
#222 205
214. SEPTIC ARTHRITIS
ï¶Bacterial inflammation of the joint space
Epidemiology
ï¶Common in children
ï¶Involve mostly knee , hip and ankle joint
Etiology
ï¶S. aures, H. influenzae, S. pneumoniae
ï¶GBS, gram-ve rods in neonates
#222 214
215. SEPTIC ARTHRITIS
Pathogenesis
ï¶Acquired mostly due to bactremia and seeding of the joint
space
ï¶Osteomyelitis and penetrative joint injury cause direct
bacterial inoculation
ï¶Bacterial proliferation, host reaction with joint neutrophilic
infiltration---joint abscess
#222 215
216. SEPTIC ARTHRITIS
Clinical manifestation
ï¶Acute joint pain, fever and irritability
ï¶Joint erythema, swelling and hotness
ï¶Tenderness on manipulation of the joint
ï¶Limitation of joint movement
#222 216
220. SEPTIC ARTHRITIS
Treatment
ï¶Pain control
ï¶Joint aspiration for treatment and diagnosis
ï¶Initiate Cloxacillin and ceftraxione
ï¶Change antibiotics based on culture
ï¶Follow for clinical response
#222 220